Clinical and Genetic Characterization of Female Dystrophinopathy

Seung Ha Lee, Jung Hwan Lee, Kyung A Lee, Young Chul Choi, Seung Ha Lee, Jung Hwan Lee, Kyung A Lee, Young Chul Choi

Abstract

Background and purpose: Duchenne and Becker muscular dystrophies are the most common X-linked recessive muscular dystrophies. Dystrophin gene mutations usually affect men, but reportedly 2.5-7.8% of women are affected and are classified as symptomatic carriers. The aim of this study was to clinically and genetically characterize symptomatic female dystrophinopathy carriers.

Methods: The clinical and genetic data of 11 female dystrophinopathy carriers among 285 patients who underwent multiplex ligation-dependent probe amplification (MLPA) analysis for the dystrophin gene were reviewed. Women with muscle weakness and/or dilated cardiomyopathy were classified as symptomatic carriers, while subjects with high serum creatine kinase (CK) levels and/or minor myopathic signs such as muscle cramps and myalgia were classified as asymptomatic.

Results: Twelve female carriers were identified, but 1 symptomatic carrier who also had Turner syndrome was excluded from the study. Of the 11 included female carriers, 4 were symptomatic and 7 were asymptomatic. The age at symptom onset in the symptomatic female carriers ranged from 15 to 31 years (mean, 30.6 years), and the age at diagnosis for asymptomatic carriers ranged from 4 to 38 years (mean, 24.5 years). Serum CK levels were markedly elevated (mean, 1,301 IU/mL) in three of the four (75%) symptomatic female carriers, and mildly elevated in three of the seven (42%) asymptomatic female carriers. Symptomatic female carriers typically presented with asymmetric bilateral leg weakness as the initial symptom, with aggravated symptoms after labor.

Conclusions: Female dystrophinopathy is not uncommon, and it is an important factor with respect to males with dystrophinopathy who may be born to such patients. Screening with MLPA is useful because it can aid in early diagnosis and appropriate management.

Keywords: dystrophinopathy; female; multiplex ligation-dependent probe amplification.

Conflict of interest statement

Conflicts of Interest: The authors have no financial conflicts of interest.

Figures

Fig. 1. Results of multiplex ligation-dependent probe…
Fig. 1. Results of multiplex ligation-dependent probe amplification analysis of the dystrophin gene in women with dystrophinopathy.

References

    1. Fujii K, Minami N, Hayashi Y, Nishino I, Nonaka I, Tanabe Y, et al. Homozygous female Becker muscular dystrophy. Am J Med Genet A. 2009;149A:1052–1055.
    1. Norman A, Harper P. A survey of manifesting carriers of Duchenne and Becker muscular dystrophy in Wales. Clin Genet. 1989;36:31–37.
    1. Hoffman EP, Arahata K, Minetti C, Bonilla E, Rowland LP. Dystrophinopathy in isolated cases of myopathy in females. Neurology. 1992;42:967–975.
    1. Hoogerwaard EM, Bakker E, Ippel PF, Oosterwijk JC, Majoor-Krakauer DF, Leschot NJ, et al. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet. 1999;353:2116–2119.
    1. Song TJ, Lee KA, Kang SW, Cho H, Choi YC. Three cases of manifesting female carriers in patients with Duchenne muscular dystrophy. Yonsei Med J. 2011;52:192–195.
    1. Cho YN, Choi YC. Female carriers of duchenne muscular dystrophy. J Genet Med. 2013;10:94–98.
    1. Tasca G, Monforte M, Iannaccone E, Laschena F, Ottaviani P, Silvestri G, et al. Muscle MRI in female carriers of dystrophinopathy. Eur J Neurol. 2012;19:1256–1260.
    1. Juan-Mateu J, Rodríguez MJ, Nascimento A, Jiménez-Mallebrera C, González-Quereda L, Rivas E, et al. Prognostic value of X-chromosome inactivation in symptomatic female carriers of dystrophinopathy. Orphanet J Rare Dis. 2012;7:82.
    1. Seemann N, Selby K, McAdam L, Biggar D, Kolski H, Goobie S, et al. Symptomatic dystrophinopathies in female children. Neuromuscul Disord. 2011;21:172–177.
    1. Cho H, Hong JM, Lee KA, Choi YC. Clinical usefulness of molecular diagnosis in dystrophin gene mutations using the multiplex ligation-dependent probe amplification (MLPA) method. J Korean Neurol Assoc. 2010;28:22–26.
    1. Yoshioka M, Yorifuji T, Mituyoshi I. Skewed X inactivation in manifesting carriers of Duchenne muscular dystrophy. Clin Genet. 1998;53:102–107.
    1. Verellen-Dumoulin C, Freund M, De Meyer R, Laterre C, Frédéric J, Thompson MW, et al. Expression of an X-linked muscular dystrophy in a female due to translocation involving Xp21 and non-random inactivation of the normal X chromosome. Hum Genet. 1984;67:115–119.
    1. Chelly J, Marlhens F, Le Marec B, Jeanpierre M, Lambert M, Hamard G, et al. De novo DNA microdeletion in a girl with Turner syndrome and Duchenne muscular dystrophy. Hum Genet. 1986;74:193–196.
    1. Quan F, Janas J, Toth-Fejel S, Johnson DB, Wolford JK, Popovich BW. Uniparental disomy of the entire X chromosome in a female with Duchenne muscular dystrophy. Am J Hum Genet. 1997;60:160–165.
    1. Katayama Y, Tran VK, Hoan NT, Zhang Z, Goji K, Yagi M, et al. Co-occurrence of mutations in both dystrophin- and androgen-receptor genes is a novel cause of female Duchenne muscular dystrophy. Hum Genet. 2006;119:516–519.
    1. Den Dunnen JT, Grootscholten PM, Bakker E, Blonden LA, Ginjaar HB, Wapenaar MC, et al. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am J Hum Genet. 1989;45:835–847.
    1. Hu XY, Ray PN, Murphy EG, Thompson MW, Worton RG. Duplicational mutation at the Duchenne muscular dystrophy locus: its frequency, distribution, origin, and phenotypegenotype correlation. Am J Hum Genet. 1990;46:682–695.
    1. Yoon J, Kim SH, Ki CS, Kwon MJ, Lim MJ, Kwon SR, et al. Carrier woman of Duchenne muscular dystrophy mimicking inflammatory myositis. J Korean Med Sci. 2011;26:587–591.
    1. Hoogerwaard EM, van der Wouw PA, Wilde AA, Bakker E, Ippel PF, Oosterwijk JC, et al. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 1999;9:347–351.
    1. Arahata K, Ishihara T, Kamakura K, Tsukahara T, Ishiura S, Baba C, et al. Mosaic expression of dystrophin in symptomatic carriers of Duchenne's muscular dystrophy. N Engl J Med. 1989;320:138–142.
    1. Magri F, Govoni A, D'Angelo MG, Del Bo R, Ghezzi S, Sandra G, et al. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J Neurol. 2011;258:1610–1623.
    1. Griggs RC, Mendell JR, Brooke MH, Fenichel GM, Miller JP, Province M, et al. Clinical investigation in Duchenne dystrophy: V. Use of creatine kinase and pyruvate kinase in carrier detection. Muscle Nerve. 1985;8:60–67.
    1. Soltanzadeh P, Friez MJ, Dunn D, von Niederhausern A, Gurvich OL, Swoboda KJ, et al. Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscul Disord. 2010;20:499–504.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever